BD is building a $ 202 million manufacturing facility in Spain

0



By
archive


Email to Andrew McIntyre

“href =” https://www.law360.com/articles/1385779/# “> Andrew McIntyre

Law360 provides free access to its coronavirus coverage to ensure that all members of the legal community have accurate information during this time of uncertainty and change. Use the form below to sign up for one of our weekly newsletters. If you sign up for one of our section newsletters, you will take part in the weekly coronavirus briefing.

Law360 (May 18, 2021, 6:00 p.m. EDT) – Becton Dickinson and Co. is to build a € 165 million ($ 201.7 million) manufacturing facility in northeastern Spain, the global medical technology company announced on Tuesday.

BD said the Zaragoza facility will have 8,000 square meters (approximately 86,000 square feet) of space upon completion of the initial expansion.

Located in the Spanish region of Aragon, Zaragoza is 195 miles northeast of Madrid and 190 miles west of Barcelona.

“BD’s new facility in Zaragoza will manufacture drug delivery devices, primarily for pharmaceutical companies supplying the European market with drugs in prefillable syringes such as vaccines and other biological drugs,” said Eric Borin, global president of BD Pharmaceutical Systems, in a statement on Tuesday . “This new facility will also add the capacity needed to support critical vaccination campaigns such as those currently taking place in response to the COVID-19 pandemic.”

BD said the facility, its fourth manufacturing facility in Spain, will initially employ 150 people and the company expects to expand the facility to 30,000 square meters and employ 600 people by 2030.

The investment in the facility is part of a broader expansion program by BD. The company announced in December 2020 that it would invest $ 1.2 billion in manufacturing facilities over the next four years. The company is expanding its prefillable syringe and advanced drug delivery system capabilities as part of this $ 1.2 billion investment program.

BD’s expansion of its manufacturing footprint comes amid a surge in investment in life science real estate. Experts recently told Law360 that they believe this sector is attractive to Sometime.

BD has been manufacturing in Spain for four decades and currently has plants in San Agustín de Guadalix, Fraga and Almaraz.

“Following BD’s announcement in December 2020 that it would build a new plant in Europe, a detailed site search process resulted in the selection of Zaragoza, Aragon, based on the optimal conditions in the region and the synergies that could be achieved with Fraga plant and the results and excellent performance of the plants currently in existence in Spain, “said Lourdes López, BD Director General for Spain and Portugal, in a statement on Tuesday.

The company makes COVID-19 vaccination injection devices at the Fraga plant, and the three facilities in Spain together have 1,500 employees and produce 10 billion medical devices annually, BD said Tuesday. The company employs 70,000 people worldwide.

Information from lawyers on the latest Zaragoza affair was not immediately available Tuesday.

– Adaptation by Stephen Berg.

For a reprint of this article, please contact [email protected]



Share.

Comments are closed.